In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
- More than 77 percent of patients in the REMfresh® Patient Reported Outcomes DURation (REMDUR) study reported achieving 6 or more hours of sleep after taking REMfresh®, the first continuous release and absorption melatonin™ (CRA-melatonin™)
-- Data from QuANTUM-R study demonstrating single agent quizartinib significantly prolongs overall survival compared to salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations to be unveiled
In U.S. patients, quinolone non-susceptibility seen in over 20 per cent of isolates from the urinary tract, driven primarily by resistance in E. coli and P. mirabilis